Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 11,803 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares of the company’s stock, valued at approximately $20,198,817.87. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Janney also recently made the following trade(s):

• On Thursday, February 26th, Daniel Janney sold 7,741 shares of Krystal Biotech stock. The stock was sold at an average price of $275.63, for a total value of $2,133,651.83.
• On Wednesday, February 25th, Daniel Janney sold 700 shares of Krystal Biotech stock. The shares were sold at an average price of $275.00, for a total value of $192,500.00.
• On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The shares were sold at an average price of $268.34, for a total value of $3,709,800.50.
• On Tuesday, February 24th, Daniel Janney sold 37,895 shares of Krystal Biotech stock. The stock was sold at an average price of $266.88, for a total value of $10,113,417.60.

Krystal Biotech Price Performance

KRYS stock traded up $4.99 during midday trading on Tuesday, reaching $263.80. 223,263 shares of the stock were exchanged, compared to its average volume of 313,065. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $298.30. The company has a fifty day moving average price of $269.38 and a 200 day moving average price of $216.90. The stock has a market capitalization of $7.71 billion, a PE ratio of 38.51 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. EFG Asset Management North America Corp. lifted its position in Krystal Biotech by 18.4% during the 3rd quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after acquiring an additional 4,217 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth about $2,705,000. Voya Investment Management LLC raised its position in Krystal Biotech by 46.7% in the 3rd quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after purchasing an additional 29,915 shares during the last quarter. Atle Fund Management AB grew its stake in shares of Krystal Biotech by 109.3% during the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock valued at $7,448,000 after purchasing an additional 22,033 shares during the last quarter. Finally, Norges Bank acquired a new stake in Krystal Biotech in the second quarter worth about $38,861,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KRYS. The Goldman Sachs Group increased their price objective on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Jefferies Financial Group boosted their price target on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $326.25.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.